Showing 2661-2670 of 6036 results for "".
- Grifols Enters Into Global Collaboration and Licensing Agreement with Selagine to Develop Immunoglobulin Eye Drops to Treat Dry Eye Diseasehttps://modernod.com/news/grifols-enters-into-global-collaboration-and-licensing-agreement-with-selagine-to-develop-immunoglobulin-eye-drops-to-treat-dry-eye-disease/2481446/Spanish pharma company Grifols announced a global collaboration and licensing agreement with Selagine to treat dry eye disease (DED) with immunoglobulin eye drops. Financial terms of the deal were not disclosed. The potential immunoglobulin treatment would be G
- New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels From Childhood Vaccineshttps://modernod.com/news/new-data-suggest-uplinza-for-the-treatment-of-nmosd-did-not-increase-the-risk-of-covid-19-or-reduce-antibody-levels-from-childhood-vaccines/2481438/Horizon Therapeutics announced new data suggest Uplinza does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies. Uplinza is the first and only B-cell-depleting monotherapy approved by the FDA and the European Commission for the tre
- EyePoint and Rallybio Partner to Evaluate Inhibitor of Complement Component 5 and Durasert Technology for Intraocular Delivery in GAhttps://modernod.com/news/eyepoint-and-rallybio-partner-to-evaluate-inhibitor-of-complement-component-5-and-durasert-technology-for-intraocular-delivery-in-ga/2481435/EyePoint Pharmaceuticals and Rallybio announced a research collaboration aimed at evaluating sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus
- Study: Low Brain Pressure Could be a Risk Factor for Developing Glaucomahttps://modernod.com/news/study-low-brain-pressure-could-be-a-risk-factor-for-developing-glaucoma/2481431/An international team of researchers led by Lithuanian scientists provide additional evidence that intracranial pressure plays an important role in normal-tension glaucoma, which accounts for up to 50 percent of all glaucoma cases. A recent clinical
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Celanese Announces a Research Agreement with Johns Hopkins University to Advance Sustained Ocular Drug Delivery to the Suprachoroidal Spacehttps://modernod.com/news/celanese-announces-a-research-agreement-with-johns-hopkins-university-to-advance-sustained-ocular-drug-delivery-to-the-suprachoroidal-space/2481417/Specialty materials and chemical company Celanese announced an agreement with Johns Hopkins University Department of Ophthalmology to collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye. A bioinert implant based on the Celanese's VitalD
- Eyenovia Announces Development Collaboration with Formosa Pharmaceuticalshttps://modernod.com/news/eyenovia-announces-development-collaboration-with-formosa-pharmaceuticals/2481412/Eyenovia announced that the company has entered into a development collaboration agreement with Taiwan-based Formosa Pharmaceuticals that seeks to combine Eyenovia’s Optejet dispensing technology with Formosa’s APNT nanoparticle formulation platform for the potential develop
- Bausch + Lomb Launches Social Media Campaign Designed to Raise Awareness of AMDhttps://modernod.com/news/bausch-lomb-launches-social-media-campaign-designed-to-raise-awareness-of-amd/2481393/Bausch + Lomb announced a new social media campaign designed to raise awareness of age-related macular degeneration (AMD). The campaign, "What Sight Inspires You," will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educat
- Endogena Therapeutics Receives FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosahttps://modernod.com/news/endogena-therapeutics-receives-fda-fast-track-designation-for-ea-2353-for-the-treatment-of-retinitis-pigmentosa/2481387/The FDA has granted Fast Track designation to Endogena Therapeutics' EA-2353 for the treatment of retinitis pigmentosa (RP). EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci